Novartis produces first batch of swine flu vax; Malaria vax positive in animal studies

Swine Flu

Novartis has produced the first batch of H1N1 vaccine in Europe using cell culture production methods. But a mass stockpile won't be ready for another two months. Report

Inovio Biomedical has forged a new collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania to further evaluate the company's DNA vaccine candidates against swine influenza A virus. Release

Some U.S. experts say that unlike Canada, America could distribute an H1N1 vaccine without an adjuvant to boost its effectiveness. Story

Vaccine Research

A new malaria vaccine that uses a weakened form of the malaria parasite has made significant preclinical progress at the Seattle Biomedical Research Institute. A test vaccine that relies on a genetically engineered parasite has proven 100 percent effective in animal studies. Report

Juvaris has taken a significant new step in its development as a vaccine company. Originally focused primarily on its experimental vaccine adjuvant JVRS-100, Juvaris announced that it has inked a collaboration deal with Antigen Discovery to identify antigen targets for new vaccines. While Juvaris has in-licensed antigens for use in new vaccines, the pact announced today gives Juvaris a path toward identifying a slate of new vaccine candidates. Report

Researchers in Canada are preparing to launch a clinical trial of an HIV/AIDS vaccine. Story

A new study could introduce a pain-free vaccination strategy that works against ear infections in children. The strategy was developed by Lauren Bakaletz, PhD, director of the Center for Microbial Pathogenesis in The Research Institute at Nationwide Children's Hospital in collaboration with John Clements, PhD, at Tulane University School of Medicine in New Orleans. Release

U.S. News & World Report profiles Harvard Med scientist Wayne Marasco, who discovered an antibody that could provide the key to a universal flu vaccine. Story

Vaccine Market

The WHO is warning that the standard TB vaccine could kill infants infected with HIV. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.